Home
Living with a chronical disease: A patient’s testimony
read more
Living with a chronical disease: A patient’s testimony
read more
Living with a chronical disease: A patient’s testimony
read more
Living with a chronical disease: A patient’s testimony
Living with Rheumatoid Arthritis: Patient Testimony
read more
Living with Rheumatoid Arthritis: Patient Testimony
read more
Living with Rheumatoid Arthritis: Patient Testimony
read more
Living with Rheumatoid Arthritis: Patient Testimony

Join our series of webinars

Beyond Biosimilars: A Holistic Approach to Inflammatory Disease
read more

Join our series of webinars

Beyond Biosimilars: A Holistic Approach to Inflammatory Disease
read more

Join our series of webinars

Beyond Biosimilars: A Holistic Approach to Inflammatory Disease
read more
Beyond Biosimilars: A Holistic Approach to Inflammatory Disease
Providing access to affordable medicines to those in need
read more
Providing access to affordable medicines to those in need
read more
Providing access to affordable medicines to those in need
read more
Providing access to affordable medicines to those in need
Fresenius Kabi is driven by one philosophy: caring for life
read more


 

Fresenius Kabi is driven by one philosophy: caring for life
read more
Fresenius Kabi is driven by one philosophy: caring for life
read more
Fresenius Kabi is driven by one philosophy: caring for life
A commitment to high-quality biosimilar development
read more
A commitment to high-quality biosimilar development
read more
A commitment to high-quality biosimilar development
read more
A commitment to high-quality biosimilar development
A life beyond disease needs a treatment to match
read more


 

A life beyond disease needs a treatment to match
read more
A life beyond disease needs a treatment to match
read more
A life beyond disease needs a treatment to match
Our commitment goes beyond treating the disease so patients can move forward
read more
Our commitment goes beyond treating the disease so patients can move forward
read more
Our commitment goes beyond treating the disease so patients can move forward
read more
Our commitment goes beyond treating the disease so patients can move forward

News

February 16, 2023

Fresenius Kabi launches biosimilar Stimufend® (pegfilgrastim-fpgk) in the U.S.
read more

February 2, 2023

Fresenius Kabi announces global license agreement with Formycon AG to commercialize proposed Ustekinumab biosimilar
read more

December 14, 2022

Fresenius Kabi receives U.S. FDA approval for biosimilar Idacio® (adalimumab)
read more

September 6, 2022

Fresenius Kabi receives U.S. FDA approval for biosimilar Stimufend® (pegfilgrastim)
read more

August 18, 2022

Fresenius Kabi announces Acceptance of its Marketing Authorization Application by the European Medicines Agency for MSB11456, a Tocilizumab Biosimilar Candidate
read more

August 10, 2022

Fresenius Kabi establishes partnership with Bio-Manguinhos/Fiocruz and Bionovis to provide access to adalimumab biosimilar in Brazil
read more

August 2, 2022

Fresenius Kabi’s Biologics License Application for Biosimilar Candidate Tocilizumab Accepted for Review by the FDA
read more

August 1, 2022

Fresenius Kabi completes majority stake acquisition of mAbxience Holding S.L., significantly enhancing presence in high-growth biopharmaceuticals market
read more

July 27, 2022

A biosimilar patient story: "I can live my life again and not feel fear"
read more

May 23, 2022

EuroPN Study: New clinical data on medical nutrition therapy in critically ill patients
read more

Our heritage

See how our consolidated expertise is used to optimize the manufacturing of essential therapies

read more

Our biosimilars

Discover how our biosimilars provide high-quality treatment and solutions for you and your patients

read more
Our commitment to patients

Our commitment to patients

Learn more about Fresenius Kabi's long-held tradition of putting patients first.

read more